bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Authors: Fu Hangcheng , Zhu Yu , Wang Yiwei , Liu Zheng , Zhang Junyu , Xie Huyang , Fu Qiang , Dai Bo , Ye Dingwei , Xu Jiejie
Published: April 2023

Represent Immunohistochemistry Images of the Three Major T Cell Categories.
Figure S3 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

Analysis of 3D-spheroid growth after GR knockdown with 1µg/ml doxycycline for 8 d in PC3, DU145, CWR22Rv1, LAPC4, and DUCaP cells (data represent Box Whisker Plots with 10-90 percentile from 3 independent experiments; ***, p< 0.001).
Figure S2 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

(A) GR knockdown confirmation by Western blot analysis using 2 specific doxycycline inducible shGR-RNA sequences (shGR-1 and shGR-2) after activation with 1 µg/ml doxycycline for 6 d in DUCaP.
Supplementary figure legend from Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
Authors: Zhang Xiyuan , Cook Katherine L. , Warri Anni , Cruz Idalia M. , Rosim Mariana , Riskin Jeffrey , Helferich William , Doerge Daniel , Clarke Robert , Hilakivi-Clarke Leena
Published: April 2023

Supplementary figure legend
Supplementary Table 1 from Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2α-mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression
Authors: Park Ki Cheong , Kim Seung Won , Jeon Jeong Yong , Jo A. Ra , Choi Hye Ji , Kim Jungmin , Lee Hyun Gyu , Kim Yonjung , Mills Gordon B. , Noh Sung Hoon , Lee Min Goo , Park Eun Sung , Cheong Jae-Ho
Published: April 2023

Primer sequences
Tables S7-S8 from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Authors: Aisner Dara L. , Sholl Lynette M. , Berry Lynne D. , Rossi Michael R. , Chen Heidi , Fujimoto Junya , Moreira Andre L. , Ramalingam Suresh S. , Villaruz Liza C. , Otterson Gregory A. , Haura Eric , Politi Katerina , Glisson Bonnie , Cetnar Jeremy , Garon Edward B. , Schiller Joan , Waqar Saiama N. , Sequist Lecia V. , Brahmer Julie , Shyr Yu , Kugler Kelly , Wistuba Ignacio I. , Johnson Bruce E. , Minna John D. , Kris Mark G. , Bunn Paul A. , Kwiatkowski David J.
Published: April 2023

Supplemental Table 7: Cases with two or more oncogenic driver alterations. Supplemental Table 8. Comparison of LCMC I and LCMC II.
Supplementary Table 1 from A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Seymour Erlene , Saiya-Cork Kamlai , Parkin Brian , Shedden Kerby , Malek Sami N.
Published: April 2023

Detailed patient characteristics and treatment details
Supplementary Methods from A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Seymour Erlene , Saiya-Cork Kamlai , Parkin Brian , Shedden Kerby , Malek Sami N.
Published: April 2023

Supplementary Methods
Supplementary Table 2 from Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Authors: Muckenhuber Alexander , Berger Anne Katrin , Schlitter Anna Melissa , Steiger Katja , Konukiewitz Björn , Trumpp Andreas , Eils Roland , Werner Jens , Friess Helmut , Esposito Irene , Klöppel Günter , Ceyhan Güralp O. , Jesinghaus Moritz , Denkert Carsten , Bahra Marcus , Stenzinger Albrecht , Sprick Martin R. , Jäger Dirk , Springfeld Christoph , Weichert Wilko
Published: April 2023

Crosstab of association of TMA-derived molecular subtypes with whole tissue slide derived subtyping.
Supplementary Figure 1 from A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Seymour Erlene , Saiya-Cork Kamlai , Parkin Brian , Shedden Kerby , Malek Sami N.
Published: April 2023

VAFs for selected genes at longitudinal time points for cases that did not receive intercurrent therapy
Supplementary Figure 5 from Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Authors: Muckenhuber Alexander , Berger Anne Katrin , Schlitter Anna Melissa , Steiger Katja , Konukiewitz Björn , Trumpp Andreas , Eils Roland , Werner Jens , Friess Helmut , Esposito Irene , Klöppel Günter , Ceyhan Güralp O. , Jesinghaus Moritz , Denkert Carsten , Bahra Marcus , Stenzinger Albrecht , Sprick Martin R. , Jäger Dirk , Springfeld Christoph , Weichert Wilko
Published: April 2023

Kaplan-Meier curves for survival differences between investigated chemotherapeutic regimens after stratification for molecular subtype of PDAC. P-values calculated by log rank test.
Figure S1 from Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials
Authors: Koster Bas D. , van den Hout Mari F.C.M. , Sluijter Berbel J.R. , Molenkamp Barbara G. , Vuylsteke Ronald J.C.L.M. , Baars Arnold , van Leeuwen Paul A.M. , Scheper Rik J. , Petrousjka van den Tol M. , van den Eertwegh Alfons J.M. , de Gruijl Tanja D.
Published: April 2023

Recurrence-free survival of patients in the two separate trials.
Supplementary Figure 3 from Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Authors: Muckenhuber Alexander , Berger Anne Katrin , Schlitter Anna Melissa , Steiger Katja , Konukiewitz Björn , Trumpp Andreas , Eils Roland , Werner Jens , Friess Helmut , Esposito Irene , Klöppel Günter , Ceyhan Güralp O. , Jesinghaus Moritz , Denkert Carsten , Bahra Marcus , Stenzinger Albrecht , Sprick Martin R. , Jäger Dirk , Springfeld Christoph , Weichert Wilko
Published: April 2023

a+b) Bar graphs of the frequencies of application of adjuvant chemotherapy in primary resected cohorts (p-value a: 0.637, b: 0.548). Y-axis depicts total number of cases. c-f) Kaplan-Meier analysis of survival effects of IHC derived subtypes after stratification for adjuvant therapy. X-axis represents survival time (in days). P-values calculated by log rank test. Ticks indicating censored cases.
Figures S1-S6 and Tables S1-S2 from Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy
Authors: Adams Daniel L. , Adams Diane K. , He Jianzhong , Kalhor Neda , Zhang Ming , Xu Ting , Gao Hui , Reuben James M. , Qiao Yawei , Komaki Ritsuko , Liao Zhongxing , Edelman Martin J. , Tang Cha-Mei , Lin Steven H.
Published: April 2023

Supplementary Figure 1. Individual and expanded images of DAPI, Cytokeratin and CD45 from Figure 2. Supplementary Figure 2. Determining the thresholds for scoring PD-L1 expression in circulating cells. Supplementary Figure 3. Average PD-L1 and RAD50 changes in each individual patient before and after induction of radiotherapy, separated by cell type. Supplementary Figure 4. Confocal imaging of RAD50 within the nuclei of a cluster of EMTCTCs from Figure 1, imaged top to bottom. Supplementary Figure 5. Distribution of RAD50 foci in cells by stage and before treatment or after treatment. Supplementary Figure 6. Percent change in pixel intensity from the T0 time point to the T1 time point. Supplementary Table 1. Patient population overview Supplementary Table 2. Tracking the longevity of PD-L1 expression levels after completion of radiotherapy.
Supplementary Table 1 from Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Authors: McDonald James E. , Kessler Marcus M. , Gardner Michael W. , Buros Amy F. , Ntambi James A. , Waheed Sarah , van Rhee Frits , Zangari Maurizio , Heuck Christoph J. , Petty Nathan , Schinke Carolina , Thanendrarajan Sharmilan , Mitchell Alan , Hoering Antje , Barlogie Bart , Morgan Gareth J. , Davies Faith E.
Published: April 2023

Baseline Characteristics of TT3a in Current and Omitted data
Supplementary Figure/Table Legend from Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Authors: McDonald James E. , Kessler Marcus M. , Gardner Michael W. , Buros Amy F. , Ntambi James A. , Waheed Sarah , van Rhee Frits , Zangari Maurizio , Heuck Christoph J. , Petty Nathan , Schinke Carolina , Thanendrarajan Sharmilan , Mitchell Alan , Hoering Antje , Barlogie Bart , Morgan Gareth J. , Davies Faith E.
Published: April 2023

Supplementary Figure/Table Legend
Supplementary Figure 1 from Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Authors: McDonald James E. , Kessler Marcus M. , Gardner Michael W. , Buros Amy F. , Ntambi James A. , Waheed Sarah , van Rhee Frits , Zangari Maurizio , Heuck Christoph J. , Petty Nathan , Schinke Carolina , Thanendrarajan Sharmilan , Mitchell Alan , Hoering Antje , Barlogie Bart , Morgan Gareth J. , Davies Faith E.
Published: April 2023

A. The distribution of TLG by molecular subgroup. The table shows the percentages and numbers of patients in each group. The Kruskal-Wallis p-value = 0.0135 indicates there is some difference in TLG among the subgroups. B. PFS (left) and OS (right) for Baseline PET Focal Lesions. C. Complete Response Duration for Baseline PET FL, TLG, and MTV. D. PFS (left) and OS (right) for Baseline MTV. E. PFS (top) and OS (bottom) for SUV max vs. baseline TLG
Supplementary Figure Legend from Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features
Authors: Hendry Shona , Pang Jia-Min B. , Byrne David J. , Lakhani Sunil R. , Cummings Margaret C. , Campbell Ian G. , Mann G. Bruce , Gorringe Kylie L. , Fox Stephen B.
Published: April 2023

Supplementary Figure Legend
Table S2 from Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Authors: Bang Yung-Jue , Cho Jae Yong , Kim Yeul Hong , Kim Jin Won , Di Bartolomeo Maria , Ajani Jaffer A. , Yamaguchi Kensei , Balogh Agnes , Sanchez Teresa , Moehler Markus
Published: April 2023

Table S2 shows Dosing Summary
Supplementary methods from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

Supplementary methods
Supplementary figure legends from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

Supplementary figure legends
Supplementary Figure 6 from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

Genetic knockdown of CXCR4 impairs the growth of NRAS/LgT derived glioma neurospheres in vitro, decreases tumor growth in vivo and increases survival of tumor-bearing animals.
Supplementary Figure 3 from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

NPC derived GBM neurospheres harbor the characteristics of Glioms Stem-Like Cells (GSLC)l.
Suppl Table 5 from The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Authors: Parpart-Li Sonya , Bartlett Bjarne , Popoli Maria , Adleff Vilmos , Tucker Laura , Steinberg Rebecca , Georgiadis Andrew , Phallen Jill , Brahmer Julie , Azad Nilo , Browner Ilene , Laheru Daniel , Velculescu Victor E. , Sausen Mark , Diaz Luis A.
Published: April 2023

Next-Generation Sequencing Performance of Plasma Isolated in Different Blood Collection Tubes
Supplementary Figure 2 from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

Tumors induced from NPCs with NRAS/LgT harbor histological hallmarks of human GBM: S.2 B.Large tumors induced with NRAS/LgT are devoid of patent vascularization.
Suppl Figure 1 from The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Authors: Parpart-Li Sonya , Bartlett Bjarne , Popoli Maria , Adleff Vilmos , Tucker Laura , Steinberg Rebecca , Georgiadis Andrew , Phallen Jill , Brahmer Julie , Azad Nilo , Browner Ilene , Laheru Daniel , Velculescu Victor E. , Sausen Mark , Diaz Luis A.
Published: April 2023

Schematic of sample collection and analyses for the comparative studies between K2EDTA (EDTA) and Streck{trade mark, serif} BCT (Streck{trade mark, serif}) tubes.
Figure S1, S2, S3 from Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
Authors: Hu Yuebi , Alden Ryan S. , Odegaard Justin I. , Fairclough Stephen R. , Chen Ruthia , Heng Jennifer , Feeney Nora , Nagy Rebecca J. , Shah Jayshree , Ulrich Bryan , Gutierrez Martin , Lanman Richard B. , Garber Judy E. , Paweletz Cloud P. , Oxnard Geoffrey R.
Published: April 2023

Supplemental Figure 1: Case of advanced NSCLC with high level EGFR T790M mutation on plasma next-generation sequencing (NGS). Supplemental Figure 2: Distribution of variant AFs between 25% and 75% across 105 cases of plasma NGS. Supplemental Figure 3: Plasma NGS cases positive for EGFR T790M submitted for blinded validation.
Supplementary Figures 1-4, Supplementary Tables 1-2, Supplementary Figure Legends from Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling
Authors: Kang Dong Woo , Lee Bo Hui , Suh Young-Ah , Choi Yong-Seok , Jang Se Jin , Kim Yong Man , Choi Kang-Yell , Min Do Sik
Published: April 2023

Figure S1 Depletion of PLD1 downregulates Wnt/β-catenin signaling via upregulation of ICAT; Figure S2 PI3K/Akt-E2F1 signaling pathways are involved in PLD1 inhibition-induced ICAT upregulation; Figure S3 PLD1-PI3K/Akt-TopBP1-E2F1 signaling pathways are involved in the regulation of ICAT expression and β-catenin/TCF transactivation; Figure S4 Immunoactivity of p-Akt, ICAT and PLD1 in PLD1 inhibitortreated PDX models; Table S1 CRC patients' clinical characteristics for primary cell culture; Table S2. Factors of multivariates variables, gender, age, organ, tumor stage, and the protein pairs using Cox's proportional hazards model.
Supplementary Figure 3B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Kwak Jae-Yong , Kim Sung-Hyun , Oh Suk Joong , Zang Dae Young , Kim Hawk , Kim Jeong-A , Do Young Rok , Kim Hyeoung Joon , Park Joon Seong , Choi Chul Won , Lee Won Sik , Mun Yeung-Chul , Kong Jee Hyun , Chung Joo Seop , Shin Ho-Jin , Kim Dae-Young , Park Jinny , Jung Chul Won , Bunworasate Udomsak , Comia Narcisa Sonia , Jootar Saengsuree , Reksodiputro Arry Harryanto , Caguioa Priscilla B. , Lee Sung-Eun , Kim Dong-Wook
Published: April 2023

Kaplan-Meier estimated progression-free survival (PFS) in the intention-to-treat population
Supplementary Figure 1B from Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Authors: Kwak Jae-Yong , Kim Sung-Hyun , Oh Suk Joong , Zang Dae Young , Kim Hawk , Kim Jeong-A , Do Young Rok , Kim Hyeoung Joon , Park Joon Seong , Choi Chul Won , Lee Won Sik , Mun Yeung-Chul , Kong Jee Hyun , Chung Joo Seop , Shin Ho-Jin , Kim Dae-Young , Park Jinny , Jung Chul Won , Bunworasate Udomsak , Comia Narcisa Sonia , Jootar Saengsuree , Reksodiputro Arry Harryanto , Caguioa Priscilla B. , Lee Sung-Eun , Kim Dong-Wook
Published: April 2023

Achievement of MMR by 12 months according to 3-month EMR (< 10% of BCR-ABL1IS). (b) Imatinib 400 mg qd (n = 78 patients with evaluable molecular data at 3 months).
Supplementary Figure S4 from Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells
Authors: Katsha Ahmed , Wang Lihong , Arras Janet , Omar Omar M. , Ecsedy Jeffrey , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

Supp Fig 4
Supplementary Figure 8 from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure 8. Schematic changes on the Notch pathway changes upon MAP17 expression A. Under normal conditions, NUMB interacts with cytoplasmic NICD, facilitating its ubiquitination and degradation. As consequence, Notch pathway is not activated. B. When MAP17 is overexpressed, its interaction with NUMB prevents NICD ubiquitination, allowing its translocation to nucleus. As consequence, Notch pathway is activated.
Supplementary Figure 4 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Authors: Soler Adriana , Figueiredo Ana M. , Castel Pau , Martin Laura , Monelli Erika , Angulo-Urarte Ana , Milà-Guasch Maria , Viñals Francesc , Baselga Jose , Casanovas Oriol , Graupera Mariona
Published: April 2023

Analysis of angiogenic islet upon genetic inactivation of p110Î±, p110Î² and p110Î' ; Supplemental Figure 4 Legend
Supplementary Figure 4 from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure 4. Transfection of T47D with a second shRNA against NUMB (shNb2) shows a similar behavior that cells transfected with shN (shNb4). A) qPCR analysis of NUMB expression in T47D cells transfected with scrambled (scr), shNb2 and shNb4. B) qPCR analysis of stem cell and Notch pathway related genes. C) shRNA Nb2 directed against NUMB increases the number of holoclones. All graphs show the average of 3 independent experiments performed in triplicate. Student's T test statistical analysis of the data was performed to find statistical differences (*=p<0.05, **=p<0.01).
Supplementary Figure 3 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Authors: Soler Adriana , Figueiredo Ana M. , Castel Pau , Martin Laura , Monelli Erika , Angulo-Urarte Ana , Milà-Guasch Maria , Viñals Francesc , Baselga Jose , Casanovas Oriol , Graupera Mariona
Published: April 2023

Survival curves upon genetic inactivation of individual p110s ; Supplemental Figure 3 Legend
Supplementary Figure 2 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Authors: Soler Adriana , Figueiredo Ana M. , Castel Pau , Martin Laura , Monelli Erika , Angulo-Urarte Ana , Milà-Guasch Maria , Viñals Francesc , Baselga Jose , Casanovas Oriol , Graupera Mariona
Published: April 2023

Analysis of GDC-0941 effects on cell proliferation ; Supplemental Figure 2 Legend
Supplementary Figure 2 from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure 2. Clonogenicity assays of HeLa and T47D cells. Left) One thousand cells were seeded in 10-cm2 plates, in triplicate and cultured for 14-20 days at 37{degree sign}C with 5% CO2. Right) Number of colonies is expressed as the average of three independent experiments performed in triplicate. Student's T test statistical analysis of the data was performed to find statistical differences (***=p<0.001).
Supplementary Figure 1 from Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors
Authors: Soler Adriana , Figueiredo Ana M. , Castel Pau , Martin Laura , Monelli Erika , Angulo-Urarte Ana , Milà-Guasch Maria , Viñals Francesc , Baselga Jose , Casanovas Oriol , Graupera Mariona
Published: April 2023

Analysis of PTEN expression in PanNETs ; Supplemental Figure 1 Legend
Supplementary Figure 1 from The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
Authors: Garcia-Heredia Jose Manuel , Lucena-Cacace Antonio , Verdugo-Sivianes Eva M. , Pérez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure 1. A. MAP17 expression in HeLa and T47D cells. Fixed cells were permeabilized and incubated with anti-MAP17 antibodies (see Material and Methods). The relative intensity of MAP17 was measured using ImageJ software. . B. MAP17 and tMAP17 detection by WB in HEK293T transfected with EV, M17 or tM17 vectors. After transfection, cells were cultured for 48 hours at 37ÂºC, and protein extracts were obtained as detailed in Material and Methods.
Supplementary Table 3 from Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Authors: Chudasama Priya , Renner Marcus , Straub Melanie , Mughal Sadaf S. , Hutter Barbara , Kosaloglu Zeynep , Schweßinger Ron , Scheffler Matthias , Alldinger Ingo , Schimmack Simon , Persigehl Thorsten , Kobe Carsten , Jäger Dirk , von Kalle Christof , Schirmacher Peter , Beckhaus Marie-Kristin , Wolf Stephan , Heining Christoph , Gröschel Stefan , Wolf Jürgen , Brors Benedikt , Weichert Wilko , Glimm Hanno , Scholl Claudia , Mechtersheimer Gunhild , Specht Katja , Fröhling Stefan
Published: April 2023

Detailed description of STS Cohort 2 including the clinical data and FGFR1 status.
Supplementary Table 2 from Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Authors: Chudasama Priya , Renner Marcus , Straub Melanie , Mughal Sadaf S. , Hutter Barbara , Kosaloglu Zeynep , Schweßinger Ron , Scheffler Matthias , Alldinger Ingo , Schimmack Simon , Persigehl Thorsten , Kobe Carsten , Jäger Dirk , von Kalle Christof , Schirmacher Peter , Beckhaus Marie-Kristin , Wolf Stephan , Heining Christoph , Gröschel Stefan , Wolf Jürgen , Brors Benedikt , Weichert Wilko , Glimm Hanno , Scholl Claudia , Mechtersheimer Gunhild , Specht Katja , Fröhling Stefan
Published: April 2023

Detailed description of STS Cohort 1 including the clinical data and FGFR1 status.
Supplementary Table 1 from Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Authors: Chudasama Priya , Renner Marcus , Straub Melanie , Mughal Sadaf S. , Hutter Barbara , Kosaloglu Zeynep , Schweßinger Ron , Scheffler Matthias , Alldinger Ingo , Schimmack Simon , Persigehl Thorsten , Kobe Carsten , Jäger Dirk , von Kalle Christof , Schirmacher Peter , Beckhaus Marie-Kristin , Wolf Stephan , Heining Christoph , Gröschel Stefan , Wolf Jürgen , Brors Benedikt , Weichert Wilko , Glimm Hanno , Scholl Claudia , Mechtersheimer Gunhild , Specht Katja , Fröhling Stefan
Published: April 2023

Soft-tissue sarcoma cohorts.
Supplementary tables from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Authors: Wang Chun-Meng , Wu Zhi-Qiang , Wang Yao , Guo Ye-Lei , Dai Han-Ren , Wang Xiao-Hui , Li Xiang , Zhang Ya-Jing , Zhang Wen-Ying , Chen Mei-Xia , Zhang Yan , Feng Kai-Chao , Liu Yang , Li Su-Xia , Yang Qing-Ming , Han Wei-Dong
Published: April 2023

Supplementary Table S1. Phonotypical characteristics of PBMCs and expanded T Cells as well as transduction efficiency of infused cell products. Supplementary Table S2. Detailed prior chemotherapy regimens for patients before CD30-CART treatment. Supplementary Table S3. Statistics of patient characteristics. Supplementary Table S4. The absolute doses of conditioning regimens for all enrolled patients. Supplementary Table S5. Toxicities possibly related to CD30-CART infusion-containing protocol. Supplementary Table S6. Maximum change from baseline of target measurable lesions. Supplementary Table S7. Clinical response in CD30-CAR T cell- treated patients.
Supplementary figure 6 from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Authors: Wang Chun-Meng , Wu Zhi-Qiang , Wang Yao , Guo Ye-Lei , Dai Han-Ren , Wang Xiao-Hui , Li Xiang , Zhang Ya-Jing , Zhang Wen-Ying , Chen Mei-Xia , Zhang Yan , Feng Kai-Chao , Liu Yang , Li Su-Xia , Yang Qing-Ming , Han Wei-Dong
Published: April 2023

Maximum reduction in target lesion size.
Supplementary figure 2 from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Authors: Wang Chun-Meng , Wu Zhi-Qiang , Wang Yao , Guo Ye-Lei , Dai Han-Ren , Wang Xiao-Hui , Li Xiang , Zhang Ya-Jing , Zhang Wen-Ying , Chen Mei-Xia , Zhang Yan , Feng Kai-Chao , Liu Yang , Li Su-Xia , Yang Qing-Ming , Han Wei-Dong
Published: April 2023

Lymphocyte recovery is a probable indictor of response.
Supplementary data [S-3] from Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients
Authors: Wang Rui , Wang Jing , Gao Ge , Hu Juan , Jiang Yuanyuan , Zhao Zhenlong , Zhang Xiaodong , Zhang Yu-Dong , Wang Xiaoying
Published: April 2023

Representative case to show the identification of leading lesion (a), where two solid tumor foci in right (red line) and left PZ (green line) were identified on axial fusion T2WI and DWI. Because tumor in right PZ had larger size than left PZ lesion, and an infiltration of the peri-prostatic fat (presence of ECE) was suspected, it was selected as leading lesion for imaging evaluation. Representative cases to show the imaging features for ECE (b), SVI (c) and local LN metastasis (d), respectively. Presence of ECE is defined as an infiltration of the peri-prostatic fat, irregular bulging associated with disruption of the capsule, focal thickening, capsular retraction, and peri-capsular spicula (arrow; b). SVI is featured with focal or diffuse low T2 SI and/or abnormal contrast enhancement within and/or along the seminal vesicle, restricted diffusion, obliteration of the angle between the base of the prostate and the seminal vesicle, and demonstration of direct tumor extension from the base of the prostate into and around the seminal vesicle (arrow; c). LN over 8 mm in short axis dimension are regarded as suspicious LN metastasis. Nodal groups including common femoral, obturator, external iliac, internal iliac, common iliac, pararectal, presacral, and para-caval, and para-aortic to the level of the aortic bifurcation were evaluated (arrow; d). Local bone metastasis was suspected if focal foci with low SI on T1WI, high SI on T2WI or DWI were noted (not shown in the figure). T = tumor; ECE = extracapsular extension; SVI = seminal vesicle invasion; LN = lymph node.
Supplementary data [S-2] from Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients
Authors: Wang Rui , Wang Jing , Gao Ge , Hu Juan , Jiang Yuanyuan , Zhao Zhenlong , Zhang Xiaodong , Zhang Yu-Dong , Wang Xiaoying
Published: April 2023

An representative case to show mp-MRI at 1.5t MR scanner. (A) axial T2WI, showing a solid tumor with hypo-signal intensity located at left middle-slice TZ (arrow). (B) axial DCE image, showing the lesion with marked enhancement at early arterial-phase imaging. (C) axial DWI at b-value of 800 sec/mm2, showing the lesion with intermediate signal intensity. (D) MRS using 3D-PRESS, showing the cancer with significant decrease in [Cit] peak.
Table S1 from A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non–Small Cell Lung Cancer
Authors: Mecklenburg Ingo , Sienel Wulf , Schmid Severin , Passlick Bernward , Kufer Peter
Published: April 2023

MAGE expression in NSCLC
Supplementary Figure Legends from Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Authors: Wongchenko Matthew J. , McArthur Grant A. , Dréno Brigitte , Larkin James , Ascierto Paolo A. , Sosman Jeffrey , Andries Luc , Kockx Mark , Hurst Stephen D. , Caro Ivor , Rooney Isabelle , Hegde Priti S. , Molinero Luciana , Yue Huibin , Chang Ilsung , Amler Lukas , Yan Yibing , Ribas Antoni
Published: April 2023

Legends
Supplementary Methods from A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non–Small Cell Lung Cancer
Authors: Mecklenburg Ingo , Sienel Wulf , Schmid Severin , Passlick Bernward , Kufer Peter
Published: April 2023

Detailed description of method and study protocol
Figure S1 from A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non–Small Cell Lung Cancer
Authors: Mecklenburg Ingo , Sienel Wulf , Schmid Severin , Passlick Bernward , Kufer Peter
Published: April 2023

Patient flow diagram
Figure S3B from Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Authors: Wongchenko Matthew J. , McArthur Grant A. , Dréno Brigitte , Larkin James , Ascierto Paolo A. , Sosman Jeffrey , Andries Luc , Kockx Mark , Hurst Stephen D. , Caro Ivor , Rooney Isabelle , Hegde Priti S. , Molinero Luciana , Yue Huibin , Chang Ilsung , Amler Lukas , Yan Yibing , Ribas Antoni
Published: April 2023

Supplementary Figure S3. Association of the cell cycle/immune signature with B, lactate dehydrogenase levels.
Supplemental figure legends and methods from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma
Authors: Hansson Jennifer , Lindgren David , Nilsson Helén , Johansson Elinn , Johansson Martin , Gustavsson Lena , Axelson Håkan
Published: April 2023

Supplemental figure legends; Fig S1 (High resolution heat-map), Fig S2 (SLC6A3 expression in relation to data in the TCGA data); Fig S3 (SLC6A3 expression and genomic copy number profiles of the CCLE repository), Fig S4 (mRNA expression of SLC6A3 in short term culture of primary ccRCC cells in hypoxia) Fig S5 (Confirmation of si-knock-down experiments) Fig S6 (Viability upon treatment with GBR12909) Supplemental method: Dissociation of human renal tissue, RNA extraction and QPCR, Dopamine uptake assay, Viability assay.
Supplemental Figure 4 from Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma
Authors: Hansson Jennifer , Lindgren David , Nilsson Helén , Johansson Elinn , Johansson Martin , Gustavsson Lena , Axelson Håkan
Published: April 2023

Relative mRNA expression of SLC6A3 in short term culture of primary ccRCC cells subjected to hypoxia.
Supplementary Data from Tumor-associated Lymphatic Endothelial Cells Promote Lymphatic Metastasis By Highly Expressing and Secreting SEMA4C
Authors: Wei Jun-Cheng , Yang Jie , Liu Dan , Wu Ming-Fu , Qiao Long , Wang Jun-Nai , Ma Quan-Fu , Zeng Zhen , Ye Shuang-Mei , Guo En-Song , Jiang Xue-Feng , You Lan-Ying , Chen Ying , Zhou Li , Huang Xiao-Yuan , Zhu Tao , Meng Li , Zhou Jian-Feng , Feng Zuo-Hua , Ma Ding , Gao Qing-Lei
Published: April 2023

The "Supplemental Data" contains supplementary methods,supplementary table 1 and supplementary figures1-19.1.Supplementary methods: Antibodies and Reagents, Primary culture of LECs, Immunomagnetic isolation of LECs, Expressing human recombinant sSEMA4C protein, Liquid chromatography - Electrospray ionization tandem MS (LC-ESI/MS), Migration assay, Wound healing assay, Cell proliferation assay, Primers sequences; 2.Supplementary Table 1: the Patient characteristics; 3.Supplementary Figure 1: the Authentication of LECs; 4.Supplementary Figure 2: the Evaluation of LCM-isolated LECs using RNA markers; 5. Supplementary Figure 3 : SEMA4C expresses on lymphatic vessels; 6.Supplementary Figure 4 : Nano-LC-ESI-MS/MS spectrum of a single charged deglycosylated glycopeptide from the culture supernatants of tumor LECs; 7. Supplementary Figure 5 :sSEMA4C binds to tumor cells and LECs; 8.Supplementary Figure 6: sSEMA4C promotes the migration and proliferation of tumor cells; 9.Supplementary Figure 7: SEMA4C promotes LECs function in vitro; 10.Supplementary Figure 8 : targeting SEMA4C inhibits LECs function in vitro; 11.Supplementary Figure 9 : the growth of the tumors; 12.Supplementary Figure 10 : Knock-down of PlexinBs; 13.Supplementary Figure 11 : Blocking ERBB2 or PlexinB2 inhibits SEMA4C-induced lymphangiogenesis in vitro; 14.Supplementary Figure 12 : LEC was stimulated by VEGF-C and sSEMA4C; 15.Supplementary Figure 13 : sSEMA4C activates MET and RHOA in tumor cells; 16.Supplementary Figure 14 : blocking MET or PlexinB2 inhibits SEMA4C-induced migration and proliferation of tumor cells; 17.Supplementary Figure 15 : cells treated with sSEMA4C; 18.Supplementary Figure 16 : targeting RHOA inhibits SEMA4C-induced lymphangiogenesis in vitro and in vivo; 19.Supplementary Figure 17 : targeting RHOA inhibits SEMA4C-induced migration of tumor cells; 20.Supplementary Figure 18 : 3 days after inoculation with tumour cells, the mice were treated with Lapatinib, K252a ,C3 toxin, Fasudil, Y27632 , sSEMA4C and PBS control solution, the size of tumor was measured; 21.Supplementary Figure 19: 3 days after inoculation with tumour cells, the mice were treated with Lapatinib, K252a ,C3 toxin, Fasudil, Y27632 , sSEMA4C and PBS control solution, the average number of positive lymph node in each mice were calculated.
Table S3 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

qRT-PCR primers
Supplementary Figure S4.1 from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Authors: Paller Channing J. , Zhou Xian C. , Heath Elisabeth I. , Taplin Mary-Ellen , Mayer Tina , Stein Mark N. , Bubley Glenn J. , Pili Roberto , Hudson Tamaro , Kakarla Radhika , Abbas Muneer M. , Anders Nicole M. , Dowling Donna , King Serina , Bruns Ashley B. , Wagner William D. , Drake Charles G. , Antonarakis Emmanuel S. , Eisenberger Mario A. , Denmeade Samuel R. , Rudek Michelle A. , Rosner Gary L. , Carducci Michael A.
Published: April 2023

Supplementary Figure S4.1 PSADT Change from Baseline in Months by MPX Treatment Group and Prior ADT Treatment
S4. Supplementary Results: Prior ADT Treatment from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Authors: Paller Channing J. , Zhou Xian C. , Heath Elisabeth I. , Taplin Mary-Ellen , Mayer Tina , Stein Mark N. , Bubley Glenn J. , Pili Roberto , Hudson Tamaro , Kakarla Radhika , Abbas Muneer M. , Anders Nicole M. , Dowling Donna , King Serina , Bruns Ashley B. , Wagner William D. , Drake Charles G. , Antonarakis Emmanuel S. , Eisenberger Mario A. , Denmeade Samuel R. , Rudek Michelle A. , Rosner Gary L. , Carducci Michael A.
Published: April 2023

Section S4 shows increased lengthening in PSADT for patients with SOD2 Ala/Ala genotype were seen in ADT naive patients.
Table S1 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

Antibodies used in the present study
S3. Methods for ellagic acid, urolithin A, quercetin, and resveratrol pharmacokinetics from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Authors: Paller Channing J. , Zhou Xian C. , Heath Elisabeth I. , Taplin Mary-Ellen , Mayer Tina , Stein Mark N. , Bubley Glenn J. , Pili Roberto , Hudson Tamaro , Kakarla Radhika , Abbas Muneer M. , Anders Nicole M. , Dowling Donna , King Serina , Bruns Ashley B. , Wagner William D. , Drake Charles G. , Antonarakis Emmanuel S. , Eisenberger Mario A. , Denmeade Samuel R. , Rudek Michelle A. , Rosner Gary L. , Carducci Michael A.
Published: April 2023

S3 provides detailed descriptions of methods used in pharmacokinetic assays.
Fig. S8 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

Knockdown efficiencies.
Supplementary methods from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
Authors: Cuppens Tine , Annibali Daniela , Coosemans An , Trovik Jone , ter Haar Natalja , Colas Eva , Garcia-Jimenez Angel , Van de Vijver Koen , Kruitwagen Roy P.M. , Brinkhuis Mariël , Zikan Michal , Dundr Pavel , Huvila Jutta , Carpén Olli , Haybaeck Johannes , Moinfar Farid , Salvesen Helga B. , Stukan Maciej , Mestdagh Carole , Zweemer Ronald P. , Massuger Leonardus F. , Mallmann Michael R. , Wardelmann Eva , Mints Miriam , Verbist Godelieve , Thomas Debby , Gommé Ellen , Hermans Els , Moerman Philippe , Bosse Tjalling , Amant Frédéric
Published: April 2023

Supplementary methods
Fig. S3 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

Evidence for self-renewal in vivo
supplementary figure 1 from Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study
Authors: Jiang Ni , Qiao Guoliang , Wang Xiaoli , Morse Michael A. , Gwin William R. , Zhou Lei , Song Yuguang , Zhao Yanjie , Chen Feng , Zhou Xinna , Huang Lefu , Hobeika Amy , Yi Xin , Xia Xuefeng , Guan Yanfang , Song Jin , Ren Jun , Lyerly H. Kim
Published: April 2023

Comparison of frequency of cfDNA
Supplementary Figure 5 from Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer
Authors: De Robertis Mariangela , Loiacono Luisa , Fusilli Caterina , Poeta Maria Luana , Mazza Tommaso , Sanchez Massimo , Marchionni Luigi , Signori Emanuela , Lamorte Giuseppe , Vescovi Angelo Luigi , Garcia-Foncillas Jesus , Fazio Vito Michele
Published: April 2023

Kaplan-Meier survival curves of EGFRhigh (dashed line) versus EGFRlow (solid line) for cohort 1, 2 and 3. P-values were calculated using log-rank tests. Tick marks represent censored data. Expression value thresholds for determining high and low groups were found through maxstat R package. For the analysis conducted only for patients belonging to EphA2high group (below figures) Hazard Ratio and 95% Confidence Intervals are reported below each cohort analysed.
Figure S6 from Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans
Authors: Mitchell Khadijah A. , Zingone Adriana , Toulabi Leila , Boeckelman Jacob , Ryan Bríd M.
Published: April 2023

Differential gene expression in AA tissues due to population stratification.
Supplementary Figure 1 from Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer
Authors: De Robertis Mariangela , Loiacono Luisa , Fusilli Caterina , Poeta Maria Luana , Mazza Tommaso , Sanchez Massimo , Marchionni Luigi , Signori Emanuela , Lamorte Giuseppe , Vescovi Angelo Luigi , Garcia-Foncillas Jesus , Fazio Vito Michele
Published: April 2023

Supplementary Figure 1 - TaqMan assays ID (Applied Biosystems)
Figure S3 from Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans
Authors: Mitchell Khadijah A. , Zingone Adriana , Toulabi Leila , Boeckelman Jacob , Ryan Bríd M.
Published: April 2023

Cross-comparison of race-enriched differential gene expression.
Supplemental Table 2 from Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome
Authors: Gasparotto Daniela , Rossi Sabrina , Polano Maurizio , Tamborini Elena , Lorenzetto Erica , Sbaraglia Marta , Mondello Alessia , Massani Marco , Lamon Stefano , Bracci Raffaella , Mandolesi Alessandra , Frate Elisabetta , Stanzial Franco , Agaj Jerin , Mazzoleni Guido , Pilotti Silvana , Gronchi Alessandro , Dei Tos Angelo Paolo , Maestro Roberta
Published: April 2023

Primers and PCR conditions
Supplemental Table 1 from Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome
Authors: Gasparotto Daniela , Rossi Sabrina , Polano Maurizio , Tamborini Elena , Lorenzetto Erica , Sbaraglia Marta , Mondello Alessia , Massani Marco , Lamon Stefano , Bracci Raffaella , Mandolesi Alessandra , Frate Elisabetta , Stanzial Franco , Agaj Jerin , Mazzoleni Guido , Pilotti Silvana , Gronchi Alessandro , Dei Tos Angelo Paolo , Maestro Roberta
Published: April 2023

Clinico-pathological features of the GISTs series
Supplementary Data, Supplementary Tables S1-S4, Supplementary Figure S1 from Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
Authors: Yuan Ying , Hess Kenneth R. , Hilsenbeck Susan G. , Gilbert Mark R.
Published: April 2023

Supplementary Data. Supplementary Table S1. Dose escalation and de-escalation thresholds for different target toxicity rates. Supplementary Table S2. Sixteen true toxicity scenarios used in the simulation study with the target DLT rate of 0.15 (left panel) and 0.3 (right panel). Supplementary Table S3. BOIN design with tighter de-escalation thresholds. Supplementary Table S4. Dose escalation and de-escalation rule for 3+3 and mTPI. Supplementary Figure S1. Sample size distribution of the 3+3 design when the true toxicity rates of 5 dose levels are 0.12, 0.2, 0.3, 0.4 and 0.5, respectively.
Table S5 from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Authors: Arbajian Elsa , Puls Florian , Antonescu Cristina R. , Amary Fernanda , Sciot Raf , Debiec-Rychter Maria , Sumathi Vaiyapuri P. , Järås Marcus , Magnusson Linda , Nilsson Jenny , Hofvander Jakob , Mertens Fredrik
Published: April 2023

Mutations found by WES on cases of 5 SEF, 4 SEF/LGFMS and 5 LGFMS; and SEF and SEF/LGFMS mutations confirmed by TSCA.
Supplemental Tables from Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma
Authors: Narayan Vivek , Keefe Stephen , Haas Naomi , Wang Le , Puzanov Igor , Putt Mary , Catino Anna , Fang James , Agarwal Neeraj , Hyman David , Smith Amanda M. , Finkelman Brian S. , Narayan Hari K. , Ewer Steven , ElAmm Chantal , Lenihan Daniel , Ky Bonnie
Published: April 2023

Supplemental Table S1. Baseline Patient Characteristics Supplemental Table S2. Univariate Analyses of Association Between Clinical Factors and Early LVEF Change on Sunitinib
Supplementary figures 1-2 from Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
Authors: Tanaka Miyuki , Tashiro Haruko , Omer Bilal , Lapteva Natasha , Ando Jun , Ngo Minhtran , Mehta Birju , Dotti Gianpietro , Kinchington Paul R. , Leen Ann M. , Rossig Claudia , Rooney Cliona M.
Published: April 2023

Supplementary Figure 1(A) VZVSTs were generated from vaccinated healthy donors (n=3) at three time points (Pre-vaccination, 1 week after and 2 weeks after vaccination); Supplementary Figure 2 (A) GD2.CAR-VZVST were cocultured with GFPffluc-LAN1 at 1:1 ratio in the presence of 20U/mL of IL-2 (1st coculture).
Supplementary figure legend from Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
Authors: Tanaka Miyuki , Tashiro Haruko , Omer Bilal , Lapteva Natasha , Ando Jun , Ngo Minhtran , Mehta Birju , Dotti Gianpietro , Kinchington Paul R. , Leen Ann M. , Rossig Claudia , Rooney Cliona M.
Published: April 2023

Supplementary figure legend
Supplementary Methods from In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets
Authors: Arbajian Elsa , Puls Florian , Antonescu Cristina R. , Amary Fernanda , Sciot Raf , Debiec-Rychter Maria , Sumathi Vaiyapuri P. , Järås Marcus , Magnusson Linda , Nilsson Jenny , Hofvander Jakob , Mertens Fredrik
Published: April 2023

This file contains the details about methods not described in the article file
Supplementary Methods from Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Authors: Byron Sara A. , Tran Nhan L. , Halperin Rebecca F. , Phillips Joanna J. , Kuhn John G. , de Groot John F. , Colman Howard , Ligon Keith L. , Wen Patrick Y. , Cloughesy Timothy F. , Mellinghoff Ingo K. , Butowski Nicholas A. , Taylor Jennie W. , Clarke Jennifer L. , Chang Susan M. , Berger Mitchel S. , Molinaro Annette M. , Maggiora Gerald M. , Peng Sen , Nasser Sara , Liang Winnie S. , Trent Jeffrey M. , Berens Michael E. , Carpten John D. , Craig David W. , Prados Michael D.
Published: April 2023

Supplementary Methods - TERT Promoter Genotyping